<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036060</url>
  </required_header>
  <id_info>
    <org_study_id>ABIDO-SOGUG</org_study_id>
    <secondary_id>2013-003811-23</secondary_id>
    <nct_id>NCT02036060</nct_id>
  </id_info>
  <brief_title>Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.</brief_title>
  <acronym>ABIDO</acronym>
  <official_title>Abiraterone Acetate Maintenance in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. Randomized Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Oncology Genito-Urinary Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Oncology Genito-Urinary Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most frequently diagnosed non-skin cancer, and the second leading&#xD;
      cause of men cancer death in the United States. Hormonal therapy remains a first-line&#xD;
      treatment for metastatic prostate cancer. Initial responses to hormonal therapy with chemical&#xD;
      or surgical castration are quite favorable, however, most patients will progress to a&#xD;
      castration-resistant phase of the disease. Docetaxel is the primary chemotherapeutic option&#xD;
      for patients with mCRPC.&#xD;
&#xD;
      Abiraterone is a novel, selective, irreversible, and potent inhibitor of&#xD;
      17-[alpha]-hydroxylase/17,20-lyase (CYP17) enzymatic activity that has recently been&#xD;
      demonstrated to further reduce testosterone levels in the blood to undetectable range (&lt; 1&#xD;
      ng/dL) and is suggested to reduce de novo intratumor androgen synthesis. Abiraterone&#xD;
      demonstrated activity in castration resistant prostate cancer patients previously treated&#xD;
      with docetaxel chemotherapy. Recently, results of a phase III trial comparing abiraterone&#xD;
      plus prednisone vs placebo plus prednisone in asymptomatic and without visceral metastasis,&#xD;
      castration-resistant metastatic prostate cancer patients, demonstrated a better radiological&#xD;
      progression free survival for abiraterone treated patients and a trend towards a better&#xD;
      survival was clear for abiraterone treated patients.&#xD;
&#xD;
      No clinical evidence exists about efficacy of chemotherapy and antiandrogen therapy&#xD;
      combination. All trials have been performed in patients in which LHRH agonist treatment was&#xD;
      continued although there is not clear evidence about efficacy of hormonal treatment. Some&#xD;
      retrospective studies suggest that androgen deprivation treatment should be maintained in&#xD;
      chemotherapy treated patients. Abiraterone has been proved to suppress androgen levels to&#xD;
      negative values, and to add efficacy to castration hormonal therapy. Combination of&#xD;
      abiraterone with docetaxel chemotherapy seems promising adding efficacy to only docetaxel&#xD;
      chemotherapy. A randomized phase II study comparing docetaxel + prednisone + abiraterone to&#xD;
      docetaxel + prednisone in mCRPC in patients treated previously with abiraterone, seems&#xD;
      promising to explore addition of efficacy to taxotere after abiraterone hormonal treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2014</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year radiologic progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time from randomization to radiologic disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologic progression free survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Time from randomization to radiologic progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA progression free survival</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Time from randomization to PSA progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>50% &amp; 90% PSA reduction from randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Response according RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life rate</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Quality of life according to FACT-P questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to skeletal-related event</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Time from randomization to skeletal-related events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to opiate use for cancer pain</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Time from randomization to opiate use for cancer pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Time from randomization to pain progression defined as an increase in median BPI score ≥ 30% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Related adverse events per patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel 75 mg/m2 + prednisone 10 mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d</intervention_name>
    <description>Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel 75 mg/m2 + prednisone 10 mg/d</intervention_name>
    <description>Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Male aged 18 years and above&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.&#xD;
&#xD;
          -  Metastatic disease documented by positive bone scan or metastatic lesions other than&#xD;
             liver or visceral metastasis on CT, MRI.&#xD;
&#xD;
          -  Prostate cancer progression to previous castration treatment documented by PSA&#xD;
             according to PCWG2 or radiographic progression according to modified RECIST criteria&#xD;
             or bone scan progression&#xD;
&#xD;
          -  Asymptomatic or mildly symptomatic from prostate cancer&#xD;
&#xD;
          -  Surgically or medically castrated, with testosterone levels of &lt; 50 ng/dL (&lt; 2.0 nM).&#xD;
&#xD;
          -  Previous anti-androgen therapy and progression after withdrawal.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
          -  Hemoglobin &gt;= 10.0 g/dL independent of transfusion&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/µL&#xD;
&#xD;
          -  Serum albumin &gt;= 3.5 g/dL&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x ULN or a calculated creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  Serum potassium &gt;= 3.5 mmol/L&#xD;
&#xD;
          -  Liver function: a. Serum bilirubin &lt; 1.5 x ULN (except for patients with documented&#xD;
             Gilbert's disease) b. AST or ALT &lt; 2.5 x ULN&#xD;
&#xD;
          -  Life expectancy of at least 6 months&#xD;
&#xD;
          -  Patients who have partners of childbearing potential must be willing to use a method&#xD;
             of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection or other medical condition that would make prednisone/prednisolone&#xD;
             (corticosteroid) use contraindicated&#xD;
&#xD;
          -  Any chronic medical condition requiring a higher dose of corticosteroid than 10mg&#xD;
             prednisone/prednisolone daily.&#xD;
&#xD;
          -  Pathological finding consistent with small cell carcinoma of the prostate&#xD;
&#xD;
          -  Liver or visceral organ metastasis&#xD;
&#xD;
          -  Known brain metastasis&#xD;
&#xD;
          -  Use of opiate analgesics for cancer-related pain, including codeine and&#xD;
             dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1&#xD;
&#xD;
          -  Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC&#xD;
&#xD;
          -  Radiation therapy for treatment of the primary tumor within 6 weeks of Cycle 1, Day&#xD;
&#xD;
          -  Radiation or radionuclide therapy for treatment of metastatic CRPC&#xD;
&#xD;
          -  Previously treated with ketoconazole for prostate cancer for greater than 7 days&#xD;
&#xD;
          -  Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4&#xD;
             weeks of Cycle 1, Day 1&#xD;
&#xD;
          -  Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1, Day 1&#xD;
&#xD;
          -  Bicalutamide (Casodex), nilutamide (Nilandron) within 6 weeks of Cycle 1 Day 1&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP &gt;= 160 mmHg or diastolic BP &gt;= 95 mmHg).&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis or chronic liver disease&#xD;
&#xD;
          -  History of pituitary or adrenal dysfunction&#xD;
&#xD;
          -  Clinically significant heart disease&#xD;
&#xD;
          -  Atrial Fibrillation, or other cardiac arrhythmia requiring therapy&#xD;
&#xD;
          -  Other malignancy, except non-melanoma skin cancer, with a &gt;= 30% probability of&#xD;
             recurrence within 24 months&#xD;
&#xD;
          -  Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, would preclude participation&#xD;
             in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A Climent, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fundación Instituto Valenciano de Oncología</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José A Arranz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel E Castellano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO 12 DE OCTUBRE,Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Begoña Mellado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL CLINIC I PROVINCIAL DE BARCELONA, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Font, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Sánchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CONSORCIO HOSPITALARIO PROVINCIAL DE CASTELLÓN, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilio Esteban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María I Sáez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL VIRGEN DE LA VICTORIA, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Santander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO MIGUEL SERVET, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Maroto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL DE LA SANTA CREU I SANT PAU, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Garcias de España, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARI SON ESPASES, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Alonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL RAMÓN Y CAJAL, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Puente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL CLÍNICO SAN CARLOS, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martín Lázaro, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEXO HOSPITALARIO UNIVERSITARIO DE VIGO, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Cassinello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO DE GUADALAJARA, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María J Méndez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO REGIONAL REINA SOFÍA, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Begoña Perez-Valderrama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO REGIONAL VIRGEN DEL ROCIO, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellón</name>
      <address>
        <city>Castellón de la Plana</city>
        <state>Castellón</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic prostate cancer</keyword>
  <keyword>Abiraterone acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

